ÂÜÀòÂÒÂ×

Charlotte joined Flagship Pioneering as an associate in 2020 after completing the summer fellowship program. Since her arrival, she has been working across the life cycle of emerging ventures in the life sciences. She works in roles ranging from ideation, scientific development, early-stage strategy, and intellectual property as part of a team of entrepreneurial scientists exploring new areas of biology to create and grow Flagship’s first-in-class bioplatforms.

At Flagship Pioneering, Charlotte is a member of the Founding Team of ProFound Therapeutics, focusing on the proteomics strategy and the proteomics team development. In addition to her role in establishing ProFound, Charlotte became a co-founder of three additional stealth-mode companies.

Prior to joining Flagship, Charlotte completed her PhD in quantitative mass spectrometry-based proteomics in the groups of Prof. Aebersold and Dr. Collins at ETH Zurich in Switzerland. During her thesis, she worked on developing and applying protein-protein interaction detection methods to study host-pathogen interactions.